Aclaris Therapeutics, Inc. (ACRS)
Company Description
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases.
The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Country | United States |
Founded | 2012 |
IPO Date | Oct 7, 2015 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 86 |
CEO | Dr. Neal S. Walker D.O., M.D. |
Contact Details
Address: 701 Lee Road, Suite 103 Wayne, Pennsylvania 19087 United States | |
Phone | 484-324-7933 |
Website | aclaristx.com |
Stock Details
Ticker Symbol | ACRS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001557746 |
CUSIP Number | 00461U105 |
ISIN Number | US00461U1051 |
Employer ID | 46-0571712 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Neal S. Walker D.O., M.D. | Co-Founder, President, Chairman and Interim Chief Executive Officer |
Dr. Joseph Monahan Ph.D. | Chief Scientific Officer |
Kevin Balthaser | Chief Financial Officer |
Matthew Rothman J.D. | General Counsel and Corporate Secretary |
Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry |
James Loerop | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 19, 2024 | 8-K | Current Report |
Feb 27, 2024 | 10-K | Annual Report |
Feb 27, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |